engleski

The treatment with nivolumab in advanced renal cancer patients – experience at the Clinic of Oncology, University Hospital Split

Background: Immunotherapy has demonstrated promising results in cancer patients. In phase III randomised trial (CheckMate 025 trial) immune checkpoint inhibition with the anti- PD-1 antibody nivolumab prolonged overall survival as compared with everolimus in advanced renal cancer patients. The toxicity profile of nivolumab was acceptable. We describe here the experience with nivolumab compassionate program at the Clinic of Oncology - University Hospital Split. Methods: A total of 25 patients with advanced renal cancer who were already treated with one or more lines of systemic therapy were included. Nivolumab dose was 3 mg/kg every two weeks. Maximal treatment duration was 2 years. All patients who received at least one dose of nivolumab were evaluated for toxicity and efficacy. Results: Median patient's age was 60 years (r 33-80). 21 (84%) patients were ECOG status 0-1 and 4 (16%) patients were ECOG status 2. There were 21 (84%) patients with lung metastases, 13 (52%) patients with bone metastases and one patient with brain metastases. Before nivolumab treatment 22/25 (88%) patients were treated with sunitinib and 10/25 (40%) patients were treated with 2 or more lines of systemic therapy. 5 patients (20%) received 1-5 cycles of nivolumab and they don't have radiological evaluation of treatment response. The response rate was 30 % (complete response in 5% and partial response in 25% of patients), while stable disease was revealed in 7 (28%) patients. Median progression free survival was 7 months. Median overall survival was 11 months. Most common adverse effects were fatique grade 1-2 in 44% of patients and anemia grade 1-2 in 24% of patients. Adverse effects grade 3 were diarrhoea in one patient and fatigue in one patient. Pneumonitis was revealed in one patient. Conclusion: Treatment with nivolumab in previously treated patients with metastatic renal cancer in every day clinical practice was effective and well tolerated.

Nivolumab, kidney cancer

nije evidentirano